The following information is furnished pursuant to both Item 2.02 and Item 7.01

On March 21, 2006, AngioDynamics, Inc. issued a press release announcing its financial results for the thirteen and thirty-nine weeks ended February 25, 2006. A copy of the release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

2

Gross profit for the third quarter of fiscal 2006 increased 35%, to $11.5 million, compared with $8.6 million for the prior year third quarter. Gross profit margin for the fiscal 2006 quarter increased 300 basis points to 58%, up from 55% for the comparable fiscal 2005 quarter. The increase in gross profit margin was largely the result of a favorable product mix from increased sales of higher margin products, such as our Morpheus CT PICC, EVENMORE dialysis catheters and VenaCure disposable kits, as well as production efficiencies resulting from continuous efforts to streamline the manufacturing process.

Operating profit for the fiscal third quarter increased 35% to $2.9 million, or 15% of net sales, compared with $2.1 million, or 14% of net sales, for the third quarter of fiscal year 2005.

“We are extremely proud to continue to post record sales, spurred by excellent unit growth across our key product lines,” commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. “We began our nationwide launch of the TOTAL ABSCESSION™ general drainage catheter in December, and with sales of $221,000 for the fiscal quarter, we are off to a healthy start.”

“We continue to be pleased with the strong uptake of our VenaCure product line for the treatment of severe varicose veins. The 81% increase in sales this quarter over the prior year third quarter is especially gratifying,” added Mr. Hobbs. “We sold 29 lasers in the fiscal third quarter and sales of our VenaCure disposable kits, which provide a significant source of high-margin recurring revenues, more than doubled over the third quarter of fiscal 2005.”

“We also began selling Sotradecol™ in mid-January to interventional radiologists, vascular surgeons and general surgeons for the treatment of small, uncomplicated varicose veins, following its showcase at the 19th Annual Congress of the American College of Phlebology meeting held in November. We expect that Sotradecol will be an important contributor to our vein treatment product line going forward,” remarked Mr. Hobbs.

As of February 25, 2006, cash and short-term investments were $28.9 million, compared with $27.1 million as of May 28, 2005. During the fiscal third quarter the Company made a final installment payment of $800,000 to Bioniche Pharma Group Limited for the licensing rights to distribute Sotradecol. Operating cash flow continues to be strong, as the Company generated $2.4 million in cash from operations during the fiscal third quarter.

For the 39 weeks ended February 25, 2006, net sales were $54.9 million, up 28% from $43.0 million for the comparable 2005 period. The increase was due to expanded sales across our diversified product line, most notably our Morpheus CT PICC, Dura-Flow dialysis catheters, and our VenaCure product line. Net income for the nine months ended February 25, 2006 was $4.8 million, up 68% from $2.9 million for the comparable fiscal 2005 period, and diluted earnings per share increased to $0.37 from $0.24, up 54%.